Showing 11 articles tagged 'STAMPEDE':

Study finds early docetaxel and abiraterone equally effective

8 Sep 2017

Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.

STAMPEDE and Latitude trial results: how will they benefit men?

6 Jun 2017

BLOG: Our CEO gives her thoughts on what new research could mean for treating prostate cancer and how Prostate Cancer UK is working to make the most of it.

New STAMPEDE trial results show earlier abiraterone could improve survival of men with advanced prostate cancer

3 Jun 2017

Announced by researchers at a cancer conference in Chicago, the new findings show earlier and combined use of existing treatments can have a significant impact on advanced disease, but questions remain about its suitability for all men.

NHS England approves upfront docetaxel for advanced prostate cancer

24 Jan 2016

Following months of intense pressure from us, clinicians and patients, NHS England finally announces that men with newly diagnosed advanced prostate cancer will now be offered immediate access to chemotherapy that could extend their lives by an average of 15 months.

Publication of STAMPEDE results means no more excuses for lack of access

22 Dec 2015

With the successful STAMPEDE trial now officially published in the Lancet, we call for upfront docetaxel treatment for men with advanced prostate cancer to be adopted across NHS England without further delay.

The fight for men to have a life-saving treatment gets to the home stretch

9 Dec 2015

BLOG: We were about to go large on the NHS's continued lack of action overs the positive results of STAMPEDE. All our campaigning machinery was set to whirl into motion. And then a sudden U-turn left us both delighted and eager to prevent similar treatments from experiencing such delays in the future, writes Karen Stalbow.

We have a golden opportunity to speed up patient access to new treatments

15 Sep 2015

BLOG: Dr Iain Frame, our Director of Research, on how the STAMPEDE trial shows why accelerated access matters and how he thinks it can be achieved.

The human cost of delayed chemotherapy

15 Sep 2015

While many hospitals delay putting into action the staggering results of the STAMPEDE trials, more than 500 men a month are missing the chance to extend their lives. We talked to one of them.

New research confirms life-prolonging benefits of earlier chemotherapy

6 Aug 2015

Men with advanced prostate cancer were found to live up to 17 months longer with docetaxel chemotherapy in addition to hormone therapy in the latest results from the CHAARTED clinical trials, fuelling demands for the NHS to make the affordable treatment the norm in the UK.

We answer your questions on exciting results from STAMPEDE trial

26 May 2015

We know the exciting results released last week from the STAMPEDE trial have raised lots of questions for men with advanced prostate cancer. So here we try to address some of these. The results showed that giving chemotherapy earlier, at the same time as hormone therapy, to men whose prostate cancer has spread beyond the prostate and the surrounding area, can help keep them alive for longer.